Seelos Therapeutics SEEL shares traded higher after news emerged the company acquired the license of gene therapy program to address Parkinson's disease from Duke University.
The gene therapy program targets the regulation of the SNCA gene. Seelos plans to study this approach, named SLS-004, initially in Parkinson’s disease.
Seelos Therapeutics shares traded higher by 12.5% to $2.51 in Thursday's pre-market session.
Related Links:
Acer Therapeutics Shares Plunge On FDA Complete Response Letter
Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.